Literature DB >> 30218137

Postoperative local fractionated radiotherapy for resected single brain metastases.

Ahmad Walid Ayas1, Stefan Grau2, Karolina Jablonska1, Daniel Ruess3, Maximilian Ruge3, Simone Marnitz1, Roland Goldbrunner2, Martin Kocher4,5,6.   

Abstract

PURPOSE: Evaluation of postoperative fractionated local 3D-conformal radiotherapy (3DRT) of the resection cavity in brain metastases. PATIENTS AND METHODS: Between 2011 and 2016, 57 patients underwent resection of a single, previously untreated (37/57, 65%) or recurrent (20/57, 35%) brain metastasis (median maximal diameter 3.5 cm [1.1-6.5 cm]) followed by 3DRT. For definition of the gross tumor volume (GTV), the resection cavity was used and for the clinical target volume (CTV), margins of 1.0-1.5 cm were added. Median dose was 48.0 Gy (30.0-50.4 Gy) in 25 (10-28) fractions; most patients had 36.0-42.0 Gy in 3.0 Gy fractions (n = 16, EQD210Gy 39.0-45.5 Gy) or 40.0-50.4 Gy in 1.8-2.0 Gy fractions (n = 37, EQD210Gy 39.3-50.0 Gy).
RESULTS: Median follow-up was 18 months. Local control rates were 83% at 1 year and 78% at 2 years and were significantly influenced by histology (breast cancer 100%, non-small lung cancer 87%, melanoma 80%, colorectal cancer 26% at 2 years, p = 0.006) and resection status (p < 0.0001), but not by EQD210Gy or size of the planning target volume (median 96.7 ml [16.7-282.8 ml]). At 1 and 2 years, 74% and 52% of the patients were free from distant brain metastases. Salvage procedures were applied in 25/27 (93%) of recurrent patients. Survival was 68% at 1 year and 41% at 2 years and was significantly improved in younger patients (p = 0.006) with higher Karnofsky performance score (p < 0.0001) and without prior radiotherapy (54% vs. 9% at 2 years, p = 0.006). No cases of radiographic or symptomatic radionecrosis were observed.
CONCLUSION: Adjuvant fractionated local 3DRT is highly effective in radiosensitive, completely resected metastases and should be considered for treating large resection cavities as an alternative to postoperative stereotactic single dose or hypofractionated radiosurgery.

Entities:  

Keywords:  Breast cancer; Malignant melanoma; Neoplasm metastasis; Non-small cell lung cancer; Survival analysis

Mesh:

Year:  2018        PMID: 30218137     DOI: 10.1007/s00066-018-1368-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  54 in total

1.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

2.  Hypofractionated stereotactic radiotherapy for brain metastases from lung cancer : Evaluation of indications and predictors of local control.

Authors:  Takeaki Ishihara; Kazunari Yamada; Aya Harada; Kenta Isogai; Yoshihiro Tonosaki; Yusuke Demizu; Daisuke Miyawaki; Kenji Yoshida; Yasuo Ejima; Ryohei Sasaki
Journal:  Strahlenther Onkol       Date:  2016-05-11       Impact factor: 3.621

3.  Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases.

Authors:  Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker
Journal:  J Neurooncol       Date:  2015-04-11       Impact factor: 4.130

4.  A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.

Authors:  Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

5.  Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.

Authors:  Eric Ojerholm; John Y K Lee; Jayesh P Thawani; Denise Miller; Donald M O'Rourke; Jay F Dorsey; Geoffrey A Geiger; Suneel Nagda; James D Kolker; Robert A Lustig; Michelle Alonso-Basanta
Journal:  J Neurosurg       Date:  2014-12       Impact factor: 5.115

6.  Current dosing paradigm for stereotactic radiosurgery alone after surgical resection of brain metastases needs to be optimized for improved local control.

Authors:  Roshan Prabhu; Hui-Kuo Shu; Constantinos Hadjipanayis; Anees Dhabaan; William Hall; Bethwel Raore; Jeffrey Olson; Walter Curran; Nelson Oyesiku; Ian Crocker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-01       Impact factor: 7.038

7.  Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery.

Authors:  Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

Review 8.  Strategy of surgery and radiation therapy for brain metastases.

Authors:  Yoshitaka Narita; Soichiro Shibui
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

9.  Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases.

Authors:  Angelika Bilger; Dusan Milanovic; Hannah Lorenz; Oliver Oehlke; Horst Urbach; Marianne Schmucker; Astrid Weyerbrock; Carsten Nieder; Anca-Ligia Grosu
Journal:  Clin Neurol Neurosurg       Date:  2016-01-14       Impact factor: 1.876

10.  Focalized external radiotherapy for resected solitary brain metastasis: does the dogma stand?

Authors:  P A Coucke; A Zouhair; M Ozsahin; N De Tribolet; R O Mirimanoff
Journal:  Radiother Oncol       Date:  1998-04       Impact factor: 6.280

View more
  6 in total

1.  Stereotactic Radiosurgery to Prevent Local Recurrence of Brain Metastasis After Surgery: Neoadjuvant Versus Adjuvant.

Authors:  Ian E McCutcheon
Journal:  Acta Neurochir Suppl       Date:  2021

2.  Evidence of dose-response following hypofractionated stereotactic radiotherapy to the cavity after surgery for brain metastases.

Authors:  Sidyarth Garimall; Mihir Shanker; Erin Johns; Trevor Watkins; Sarah Olson; Michael Huo; Matthew C Foote; Mark B Pinkham
Journal:  J Neurooncol       Date:  2020-01-06       Impact factor: 4.130

3.  Brain metastases from esophageal cancer: A retrospective analysis of the outcome after surgical resection followed by radiotherapy.

Authors:  Pantelis Stavrinou; Lars Plambeck; Martin Proescholdt; Markus Ghadimi; Roland Goldbrunner; Stefan Grau
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889

4.  Stereotactic Cavity Irradiation or Whole-Brain Radiotherapy Following Brain Metastases Resection-Outcome, Prognostic Factors, and Recurrence Patterns.

Authors:  Rami A El Shafie; Thorsten Dresel; Dorothea Weber; Daniela Schmitt; Kristin Lang; Laila König; Simon Höne; Tobias Forster; Bastian von Nettelbladt; Tanja Eichkorn; Sebastian Adeberg; Jürgen Debus; Stefan Rieken; Denise Bernhardt
Journal:  Front Oncol       Date:  2020-05-08       Impact factor: 6.244

5.  Cyberknife® hypofractionated stereotactic radiosurgery (CK-hSRS) as salvage treatment for brain metastases.

Authors:  Sergej Telentschak; Daniel Ruess; Stefan Grau; Roland Goldbrunner; Niklas von Spreckelsen; Karolina Jablonska; Harald Treuer; Martin Kocher; Maximilian Ruge
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-26       Impact factor: 4.553

6.  The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting.

Authors:  Stephanie T Jünger; Lenhard Pennig; Petra Schödel; Roland Goldbrunner; Lea Friker; Martin Kocher; Martin Proescholdt; Stefan Grau
Journal:  Cancers (Basel)       Date:  2021-03-21       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.